At the end of the latest market close, Sutro Biopharma Inc. (STRO) was valued at $10.10. In that particular session, Stock kicked-off at the price of $10.25 while reaching the peak value of $11.31 and lowest value recorded on the day was $9.98. The stock current value is $11.27.
Recently in News on September 2, 2020, Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Global Meeting. – Ongoing Data Further Demonstrate Promising Efficacy and Safety Profile in a Heavily Pretreated Patient Population Not Selected Based on Receptor Expression. You can read further details here
Sutro Biopharma Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $12.75 on 01/06/20, with the lowest value was $6.00 for the same time period, recorded on 03/19/20.
Sutro Biopharma Inc. (STRO) full year performance was 40.64%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Sutro Biopharma Inc. shares are logging -11.65% during the 52-week period from high price, and 87.75% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $6.00 and $12.75.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1081769 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Sutro Biopharma Inc. (STRO) recorded performance in the market was 2.41%, having the revenues showcasing 13.10% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 383.69M, as it employees total of 177 workers.
Market experts do have their say about Sutro Biopharma Inc. (STRO)
During the last month, 8 analysts gave the Sutro Biopharma Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 9.19, with a change in the price was noted +1.33. In a similar fashion, Sutro Biopharma Inc. posted a movement of +13.33% for the period of last 100 days, recording 173,583 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for STRO is recording 0.12 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.12.
Technical breakdown of Sutro Biopharma Inc. (STRO)
Raw Stochastic average of Sutro Biopharma Inc. in the period of last 50 days is set at 98.94%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 98.53%. In the last 20 days, the company’s Stochastic %K was 93.79% and its Stochastic %D was recorded 92.43%.
Bearing in mind the latest performance of Sutro Biopharma Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 2.41%. Additionally, trading for the stock in the period of the last six months notably improved by 16.98%, alongside a boost of 40.64% for the period of the last 12 months. The shares increased approximately by 20.61% in the 7-day charts and went down by 32.69% in the period of the last 30 days. Common stock shares were driven by 13.10% during last recorded quarter.